These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23394381)

  • 1. Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.
    Franchini M; Frattini F; Crestani S; Bonfanti C
    Hematology; 2013 Jul; 18(4):183-90. PubMed ID: 23394381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How we treat a hemophilia A patient with a factor VIII inhibitor.
    Kempton CL; White GC
    Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a.
    Gouw SC; Fijnvandraat K
    Semin Thromb Hemost; 2013 Oct; 39(7):740-51. PubMed ID: 24014072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 7. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
    Franchini M; Coppola A; Rocino A; Santagostino E; Tagliaferri A; Zanon E; Morfini M;
    Semin Thromb Hemost; 2013 Oct; 39(7):752-66. PubMed ID: 24022806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
    Ishiguro A
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A close insight to factor VIII inhibitor in the congenital hemophilia A.
    Tabriznia-Tabrizi S; Gholampour M; Mansouritorghabeh H
    Expert Rev Hematol; 2016 Sep; 9(9):903-13. PubMed ID: 27367203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
    Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
    Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
    Kruse-Jarres R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():407-12. PubMed ID: 22160066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reversal of inhibitors in congenital hemophilia.
    DeFrates SR; McDonagh KT; Adams VR
    Pharmacotherapy; 2013 Feb; 33(2):157-64. PubMed ID: 23355059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.
    DiMichele DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S30-3. PubMed ID: 23109404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.